NCODA Logo

The purpose of this PQI is to review clinical considerations around the use of glofitamab-gxbm in the treatment of relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma.